✦ LIBER ✦

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

✍ Scribed by Susan M. Chang; Kathleen R. Lamborn; Mary Malec; David Larson; William Wara; Penny Sneed; Jane Rabbitt; Margaretta Page; M.Kelly Nicholas; Michael D. Prados

Book ID: 108148385
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 74 KB
Volume: 60
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2004.04.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of erlotinib with temozol

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

✍ David M. Peereboom; Dale R. Shepard; Manmeet S. Ahluwalia; Cathy J. Brewer; Neer 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 180 KB

Phase II study of thalidomide and radiat

Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme

✍ Christopher D. Turner; Susan Chi; Karen J. Marcus; Tobey MacDonald; Roger J. Pac 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 199 KB

Phase II study of temozolomide without r

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population

✍ Carol Alliot 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

Phase II study of temozolomide without r

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

✍ Olivier-L. Chinot; Maryline Barrie; Elisabeth Frauger; Henry Dufour; Dominique F 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND Currently, the survival of patients age > 70 years with glioblastoma multiforme (GBM) ranges from 4 months to 6 months, although radiotherapy and/or chemotherapy may prolong survival in certain subgroups. Temozolomide is an oral chemotherapeutic agent with efficacy agains

A pilot study of hypofractionated radiat

A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme

✍ Mizuhiko Terasaki; Tomoko Eto; Shinji Nakashima; Yosuke Okada; Etsuyo Ogo; Yasuo 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 207 KB

Phase II study of fixed dose rate gemcit

Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme

✍ Giulio Metro; Alessandra Fabi; Maria A. Mirri; Antonello Vidiri; Andrea Pace; Ma 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 312 KB